{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T12:28:03Z","timestamp":1778070483392,"version":"3.51.4"},"reference-count":22,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2023,2,27]],"date-time":"2023-02-27T00:00:00Z","timestamp":1677456000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background: Hepatic arterial infusion chemotherapy (HAIC) has been proven to be an effective treatment for advanced HCC. In this study, we present our single-center experience of implementing combined sorafenib and HAIC treatment for these patients and compare the treatment benefit with that of sorafenib alone. Methods: This was a retrospective single-center study. Our study included 71 patients who started taking sorafenib between 2019 and 2020 at Changhua Christian Hospital in order to treat advanced HCC or as a salvage treatment after the failure of a previous treatment for HCC. Of these patients, 40 received combined HAIC and sorafenib treatment. The efficacy of sorafenib alone or in combination with HAIC was measured in regard to overall survival and progression-free survival. Multivariate regression analysis was performed to identify factors associated with overall survival and progression-free survival. Results: HAIC combined with sorafenib treatment and sorafenib alone resulted in different outcomes. The combination treatment resulted in a better image response and objective response rate. Moreover, among the patients aged under 65 years old and male patients, the combination therapy resulted in a better progression-free survival than sorafenib alone. A tumor size \u2265 3 cm, AFP &gt; 400, and ascites were associated with a poor progression-free survival among young patients. However, the overall survival of these two groups showed no significant difference. Conclusions: Combined HAIC and sorafenib treatment showed a treatment effect equivalent to that of sorafenib alone as a salvage treatment modality used to treat patients with advanced HCC or with experience of a previously failed treatment.<\/jats:p>","DOI":"10.3390\/jcm12051887","type":"journal-article","created":{"date-parts":[[2023,3,6]],"date-time":"2023-03-06T03:02:32Z","timestamp":1678071752000},"page":"1887","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Combining HAIC and Sorafenib as a Salvage Treatment for Patients with Treatment-Failed or Advanced Hepatocellular Carcinoma: A Single-Center Experience"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7725-3565","authenticated-orcid":false,"given":"Chia-Bang","family":"Chen","sequence":"first","affiliation":[{"name":"Department of Medical Imaging, Changhua Christian Hospital, Changhua 500, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5153-8375","authenticated-orcid":false,"given":"Chun-Min","family":"Chen","sequence":"additional","affiliation":[{"name":"Big Data Center, Changhua Christian Hospital, Changhua 500, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruo-Han","family":"Tzeng","sequence":"additional","affiliation":[{"name":"Department of Hematology, Changhua Christian Hospital, Changhua 500, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chen-Te","family":"Chou","sequence":"additional","affiliation":[{"name":"Department of Medical Imaging, Changhua Christian Hospital, Changhua 500, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pei-Yuan","family":"Su","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology & Hepatology, Changhua Christian Hospital, Changhua 500, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"You-Chuen","family":"Hsu","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology & Hepatology, Changhua Christian Hospital, Changhua 500, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheng-Da","family":"Yang","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology & Hepatology, Changhua Christian Hospital, Changhua 500, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,2,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1001\/jamaoncol.2017.3055","article-title":"The Burden of Primary Liver Cancer and Underlying Etiologies from 1990 to 2015 at the Global, Regional, and National Level: Results from the Global Burden of Disease Study 2015","volume":"3","author":"Akinyemiju","year":"2017","journal-title":"JAMA Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"ref_3","first-page":"e19274","article-title":"Hepatocellular Carcinoma in 2021: An Exhaustive Update","volume":"13","author":"Philips","year":"2021","journal-title":"Cureus"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"299","DOI":"10.20892\/j.issn.2095-3941.2017.0177","article-title":"Yttrium-90 transarterial radioembolization versus conventional transarterial chemoembolization for patients with hepatocellular carcinoma: A systematic review and meta-analysis","volume":"15","author":"Yi","year":"2018","journal-title":"Cancer Biol. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"S361","DOI":"10.21037\/jgo.2020.02.08","article-title":"Addressing the worldwide hepatocellular carcinoma: Epidemiology, prevention and management","volume":"12","author":"Samant","year":"2021","journal-title":"J. Gastrointest. Oncol."},{"key":"ref_6","first-page":"165","article-title":"Efficacy of sequential sorafenib plus hepatic arterial infusion chemotherapy in patients with Barcelona Clinic Liver Cancer stage B and C hepatocellular carcinoma: A retrospective single-institution study","volume":"22","author":"Ikuta","year":"2018","journal-title":"Contemp. Oncol. Pozn."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1093\/jjco\/hyz069","article-title":"Sorafenib versus hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma: A systematic review and meta-analysis","volume":"49","author":"Zhuang","year":"2019","journal-title":"Jpn. J. Clin. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.31557\/APJCP.2020.21.6.1797","article-title":"The Prognosis of Hepatocellular Carcinoma Treated with Sorafenib in Combination with TACE","volume":"21","author":"Kimura","year":"2020","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1001\/jamaoncol.2019.2792","article-title":"Assessment of Treatment with Sorafenib Plus Doxorubicin vs Sorafenib Alone in Patients with Advanced Hepatocellular Carcinoma: Phase 3 CALGB 80802 Randomized Clinical Trial","volume":"5","author":"Shi","year":"2019","journal-title":"JAMA Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1148\/radiol.211545","article-title":"Sorafenib Plus Hepatic Arterial Infusion Chemotherapy versus Sorafenib for Hepatocellular Carcinoma with Major Portal Vein Tumor Thrombosis: A Randomized Trial","volume":"303","author":"Zheng","year":"2022","journal-title":"Radiology"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"571","DOI":"10.4254\/wjh.v10.i9.571","article-title":"Treatment strategies for advanced hepatocellular carcinoma: Sorafenib vs hepatic arterial infusion chemotherapy","volume":"10","author":"Saeki","year":"2018","journal-title":"World J. Hepatol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"3843","DOI":"10.3748\/wjg.v21.i13.3843","article-title":"Hepatic artery infusion chemotherapy for advanced hepatocellular carcinoma","volume":"21","author":"Song","year":"2015","journal-title":"World J. Gastroenterol."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Tsai, W.-L., Lai, K.-H., Liang, H.-L., Hsu, P.-I., Chan, H.-H., Chen, W.-C., Yu, H.-C., Tsay, F.-W., Wang, H.-M., and Tsai, H.-C. (2014). Hepatic Arterial Infusion Chemotherapy for Patients with Huge Unresectable Hepatocellular Carcinoma. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0092784"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/S2468-1253(18)30078-5","article-title":"Sorafenib plus low-dose cisplatin and fluorouracil hepatic arterial infusion chemotherapy versus sorafenib alone in patients with advanced hepatocellular carcinoma (SILIUS): A randomised, open label, phase 3 trial","volume":"3","author":"Kudo","year":"2018","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1055\/s-0030-1247132","article-title":"Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma","volume":"30","author":"Lencioni","year":"2010","journal-title":"Semin. Liver Dis."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Niu, M., Yi, M., Li, N., Wu, K., and Wu, K. (2021). Advances of Targeted Therapy for Hepatocellular Carcinoma. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.719896"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1111\/jgh.14152","article-title":"Comparison of clinical outcome of hepatic arterial infusion chemotherapy and sorafenib for advanced hepatocellular carcinoma according to macrovascular invasion and transcatheter arterial chemoembolization refractory status","volume":"33","author":"Kodama","year":"2018","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"52","DOI":"10.21037\/tgh.2019.12.19","article-title":"Value of alpha-fetoprotein in hepatocellular carcinoma","volume":"6","author":"Lee","year":"2021","journal-title":"Transl. Gastroenterol. Hepatol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"16343","DOI":"10.1038\/s41598-021-95835-5","article-title":"Tumor size may influence the prognosis of solitary hepatocellular carcinoma patients with cirrhosis and without macrovascular invasion after hepatectomy","volume":"11","author":"Liang","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1084\/jem.20190441","article-title":"Gender disparity in HCC: Is it the fat and not the sex?","volume":"216","author":"Greten","year":"2019","journal-title":"J. Exp. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"100695","DOI":"10.1016\/j.aohep.2022.100695","article-title":"Gender disparity in hepatocellular carcinoma recurrence after curative hepatectomy","volume":"27","author":"Liang","year":"2022","journal-title":"Ann. Hepatol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1097\/JCMA.0000000000000722","article-title":"Differential prognoses among male and female patients with hepatocellular carcinoma","volume":"85","author":"Liao","year":"2022","journal-title":"J. Chin. Med. Assoc."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/5\/1887\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:43:58Z","timestamp":1760121838000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/5\/1887"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,27]]},"references-count":22,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,3]]}},"alternative-id":["jcm12051887"],"URL":"https:\/\/doi.org\/10.3390\/jcm12051887","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,27]]}}}